Eiko Lifesciences Limited · BSE:EIKO
Eiko Lifesciences — Q4 FY2020-21 Earnings Presentation
18 slides from Eiko Lifesciences's earnings presentation, 2021
Slide 1: Investor's Presentation
INVESTOR’S PRESENTATION “Eiko LifeSciences” is a division of Narendra Investments (Delhi) Ltd., BSE Code: NIDL | 540204 |
Slide 2: Safe Harbor
SAFE HARBOR This presentation and the accompanying slides (the “Presentation”), which have been prepared by Eiko LifeSciences (a division of Narendra Investments (Delhi) Ltd.) (the “Company”), solely for information purposes and do not constitute any offer, recommendation or invitation to purchase o
Slide 3: The Ethos - Vision and Mission
The Ethos- Vision and Mission 3
Slide 4: About the Company
ABOUT THE COMPANY Narendra Investments (Delhi) Ltd. Incorporated in 1977 (BSE Code: NIDL | 540204 |) has recently ventured in the business of Manufacturing, Supplying and Export of Speciality & Fine Chemicals. Company has formed a separate division namely “Eiko LifeSciences” by amending the main obj
Slide 5: Company Overview
Company Overview 5
Slide 6: Company overview: speciality chemicals manufacturer and exporter
In a short span of time, company has established itself in the race of becoming India's leading Speciality & Fine Chemicals Manufacturer, Supplier & Exporting company. ➢ Company’s Speciality Chemicals product offerings comprise of Organic as well as and Inorganic chemicals. ➢ Its products are used i
Slide 7: Q-4/FY 20-21 Financial Performance
Q-4/ FY 20-21 Financial Performance 7
Slide 8: Quarter and year ended financial results (₹ in Lakhs)
(₹ in Lakhs) Quarter ended Year ended Sr. Particulars No. 31.03.2021 31.12.2020 Change % 31.03.2021 1 Revenue from operations 614.47 584.59 5% 1,199.06 Profit/(Loss) from ordinary 2 activities before tax 48.55 27.69 75% 83.27 3 EBITDA 55.64 31.32 78% 98.21 4 EBITDA Margin 9.05% 5.36% 69% 8% Profit/(
Slide 9: Our Products & Business
Our Products & Business 9
Slide 10: Our Business Profile
OUR Business Profile Our Business is broadly categorized Company is also Intermediates for proposing to venture Pharmaceuticals, into APIs business, Fine Chemicals & as a part of forward Agrochemicals integration strategy 10
Slide 11: Our Products Profile
OUR Products Profile 3-Chloropropiophenone, Orthochlorobenzonitrile Fine Chemicals Agrochemicals intermediates (2-Chlorobenzonitrile Halogenated products such as used for perfumery, food & Used in manufacturing of Bromo/ Chloro derivatives of flavor Industry such as Coumarin Speciality Fungicides an
Slide 12: End Users of Our Products
End users of our Products 13
Slide 13: End-user industries
PHARMACEUTICALS NUTRACEUTICALS AGRO CHEMICALS CONSTRUCTION CHEMICALS DYES & PIGMENTS FLAVORS & FRAGRANCES
Slide 14: Competitive Advantages
Competitive Advantages 15
Slide 15: Eiko LifeSciences Competitive Advantages
Eiko Large and diverse array of products LifeSciences has the Strong relations with Manufacturing facilities following Diversified and Stable Customer Base Competitive Advantages: Strong Relations with Marquee Clients Experienced team with domain knowledge Established and stable relationship with su
Slide 16: Experienced Promoters, Board of Directors and KMPs
Experienced Promoters, Board of Directors and KMPs 17
Slide 17: Board of Directors and Promoters
Operations of the Company are being professionally managed by a team of experienced technocrats under guidance from Board of Directors/ Promoters ➢ CA Laxmikant Kabra (Chairman, Promoter Director) ➢ Mr. Bhavesh Dhirajlal Tanna (Promoter Director) ➢ Mr. Umesh More (Executive Director) ➢ Ms. Kajal Kot
Slide 18: Thanks! Any questions?
Thanks! Any questions? You can find us at: business@eikolifesciences.com 19
Eiko LifeSciences — Q4 FY2020-21 Earnings Presentation on 6ix